A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome.
Saeed AlZabaliSawsan AlBatatiKhawla RahimHassan FaqeehiAbubaker OsmanAbdulaziz BamhrazMohammed A SalehJameela A KariMajed AloufiLoai EidHaydar NasserAbubakr ImamEntesar AlHammadiOmar AlkandariMohamed S Al RiyamiSidharth Kumar SethiChristoph LichtKhalid A AlhasanAbdulkarim AlAnaziPublished in: Children (Basel, Switzerland) (2022)
The discontinuation of eculizumab in patients with aHUS is not without risk; it can result in HUS recurrence. Eculizumab discontinuation can be performed with close monitoring of the patients. It is essential to assess risk the factors for relapse before eculizumab discontinuation, in particular in children with a positive complement variant and any degree of residual CKD, as HUS relapse may lead to additional loss of kidney function. Resuming eculizumab promptly after relapse is effective in most patients.